Navigation Links
Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Date:8/6/2012

323.11 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - Spain 333.12 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - Spain 343.13 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - The UK 353.14 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - The UK 363.15 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - Japan 373.16 Retinal Vein Occlusion Therapeutics Market Forecast (2010- 2019) - Japan 383.17 Drivers and Barriers for the Retinal Vein Occlusion Therapeutics Market 393.17.1 Drivers for the Retinal Vein Occlusion Therapeutics Market 393.17.2 Barriers for the Retinal Vein Occlusion Therapeutics Market 393.17.3 Opportunity and Unmet Need Analysis 403.18 Key Takeaway 404 Retinal Vein Occlusion Therapeutics - Competitive Assessment 414.1 Overview 414.2 Strategic Competitor Assessment 414.3 Product Profiles for the Major Marketed Products in the Retinal Vein Occlusion Therapeutics Market 424.3.1 Lucentis (ranibizumab) 424.3.2 Ozurdex (dexamethasone intravitreal implant) 434.3.3 Avastin (bevacizumab) 454.4 Key Takeaway 455 Retinal Vein Occlusion Therapeutics - Pipeline Assessment 465.1 Overview 465.2 Strategic Pipeline Assessment 465.3 Retinal Vein Occlusion Therapeutics Pipeline - Pipeline by Phase of Development 475.3.1 Retinal Vein Occlusion Therapeutics - Phase III Pipeline 475.3.2 Retinal Vein Occlusion Therapeutics - Phase II/III Pipeline 475.3.3 Retinal Vein Occlusion Therapeutics - Phase II Pipeline 485.3.4 Retinal Vein Occlusion Therapeutics - Phase I/II 485.4 Retinal Vein Occlusion Therapeutics Market - Pipeline by Mechanism of Action 495.5 Technology Trends Analytic Framework 505.6 Retinal Vein Occlusion Therapeutics - Promising Drugs under Clinical Development 515.7 Molecule Profile for Promising Drugs under Clinical Development 525.7.1 Eylea (aflibercept injection) 525.8 Key Takeaway 536 Retinal Vein Occlusion Therapeutics - Clinical Trials Mapping 546.1 Clinical Trial Mapping Over
'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
5. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
6. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
7. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
8. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
9. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... BELMONT, Calif. , July 21, 2014 /PRNewswire/ ... world,s first fluid-based accommodating intraocular lens, today announced ... Allen, Mosbacher, and Law Chair of Ophthalmology, and ... has joined the company,s Scientific Advisory Board. ... honors, including the American Academy of Ophthalmology Lifetime ...
(Date:7/21/2014)... , July 21, 2014  Zacks.com announces the list of ... Equity Research analysts discuss the latest news and events impacting ... blog include the Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH - Free ... ), Eli Lilly and Company (NYSE: LLY - Free ... and InterMune, Inc. (Nasdaq: ITMN - Free Report ). ...
(Date:7/21/2014)... , July 21, 2014   Regulus ... biopharmaceutical company leading the discovery and development of ... U.S. Food & Drug Administration (FDA) has granted ... chemically modified oligonucleotide that binds to and inhibits ... for the treatment of Alport syndrome, a life-threatening ...
Breaking Medicine Technology:PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 2PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 3PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 4The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 2The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 3The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 4The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 5The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 6The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 7Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5
... Feb. 8, 2011 DURECT Corporation (Nasdaq: ... has launched commercial sales of its Food and Drug ... injectable animal health drug utilizing DURECT,s SABER™ technology to ... on net sales of SucroMate and will supply one ...
... DIEGO, Feb. 8, 2011 Anadys Pharmaceuticals, Inc. (Nasdaq: ... the 13th Annual Bio CEO & Investor Conference on Tuesday, ...  The conference is being held at the Waldorf-Astoria Hotel in ... Officer of Anadys, will provide an overview of Anadys and ...
Cached Medicine Technology:DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product 2DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product 3Anadys Pharmaceuticals to Present at the Bio CEO & Investor Conference 2
(Date:7/21/2014)... for Public Affairs Research has released the results of ... it means to be a quality health care provider ... Robert Wood Johnson Foundation, sheds new light on how ... and doctors, as well as the information they use ... produces new and actionable data during a crucial period ...
(Date:7/21/2014)... Western University of Health Sciences ... For” by the Chronicle of Higher Education for ... Honor Roll for the first time. , WesternU ... and Benefits, Confidence in Senior Leadership, Job Satisfaction, ... “Western University of Health Sciences is a great ...
(Date:7/21/2014)... -- Good parenting and life skills coaching seem ... a new study suggests. Inflammation is a ... to a number of illnesses, according to Northwestern ... childhood and adulthood involve excessive inflammation. The process ... and some cancers," study author Gregory Miller, a ...
(Date:7/21/2014)... A new study suggests that potential help in ... your refrigerator. The study found that regular intake ... or supplements, may help ease the condition. Researchers ... between probiotics and blood pressure. The studies involved a ... blood pressure. People who consumed probiotics had an ...
(Date:7/21/2014)... may be getting women to go to the hospital more ... shows women have longer hospital stays and are more likely ... attack. , In the study published online today in the ... from Yale School of Medicine analyzed 230,684 hospitalizations for heart ... of 1.1 million hospitalizations reported in a national database from ...
Breaking Medicine News(10 mins):Health News:National survey from AP-NORC examines perceptions of health care provider quality 2Health News:Western University of Health Sciences Elevated to “Great College to Work For” Honor Roll 2Health News:Life Skills, Parenting Classes May Cut Inflammation in Poor Kids 2Health News:Could Probiotics Help Tame High Blood Pressure? 2
... to Cover Medical Devices, ARLINGTON, Va., Nov. 2 ... Capital Markets) today announced that,Christopher Warren has joined FBR ... Analyst within its healthcare group and will,focus on the ... of experience in equity research, and we,value the disciplined, ...
... Vanda Pharmaceuticals,Inc. (Nasdaq: VNDA ) announced ... offer convertible senior notes. The decision not to ... due principally to prevailing,market conditions resulting in note ... Note Regarding Forward-Looking Statements This release contains ...
... Pa., Nov. 2 Kensey Nash Corporation,(Nasdaq: ... licensed U.S. patent,6,175,669, Optical Coherence Domain Reflectometry Guidewire, ... the intellectual,property portfolio related to its chronic total ... enhanced optical sensing capabilities,allowing it to sense locations, ...
... Just how much of the time,that sales people should be ... internal communication? Pharmaceutical sales directors agree the answer is ... for internal communication - or 6 weeks per rep,per year ... year,according to a recent research study by Best Practices, LLC. ...
... inhibitor demonstrates >99% mean decrease in HCV RNA ... with no serious adverse events-, ... the results of a 14-day Phase 1 multiple ascending,dose monotherapy study ... study, being presented as a "late-breaker" abstract at,the 58th Annual Meeting ...
... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) will announce ... 8, 2007, after market close. The announcement ... followed by a conference call and live webcast ... 4:30 p.m. Eastern. Interested parties may access the,live ...
Cached Medicine News:Health News:FBR Capital Markets Hires Senior Healthcare Analyst 2Health News:Vanda Pharmaceuticals Announces that it No Longer Intends to Offer Convertible Senior Notes 2Health News:Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform 2Health News:Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform 3Health News:New Pharmaceutical Sales Force Communication Metrics: Nearly 6 Weeks of Sales Time per Rep Wasted Each Year 2Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 2Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 3Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 4Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 5Health News:Kosan Announces November 8, 2007 Conference Call and Webcast of Third Quarter 2007 Financial Results 2
... Apron has standard front protection. ... from the shoulders to the ... a 6" wide elastic belt. ... apron snug. Belts may be ...
... new Breast Overlay Apron ... provide extra coverage for ... adjustable velcro flaps allow ... fit, plust added coverage ...
Lap pad used to protect pelvic regions...
... necessary, the Two-Piece should be your ... comfort through more efficient distribution of ... vest comes with shoulder pads and ... well as an attached belt to ...
Medicine Products: